Gut microbial predictors of first-line immunotherapy efficacy in advanced NSCLC patients

Abstract The composition of the gut microbiome of patients with advanced non-small cell lung cancer is currently considered a factor influencing the effectiveness of treatment with immune checkpoint inhibitors. We aimed to evaluate the baseline gut microbiome composition in patients before receiving...

書目詳細資料
發表在:	Scientific Reports
Main Authors:	Anna Grenda, Ewelina Iwan, Barbara Kuźnar-Kamińska, Arkadiusz Bomba, Katarzyna Bielińska, Paweł Krawczyk, Izabela Chmielewska, Małgorzata Frąk, Michał Szczyrek, Anna Rolska-Kopińska, Tomasz Jankowski, Robert Kieszko, Janusz Milanowski
格式:	Article
語言:	英语
出版:	Nature Portfolio 2025-02-01
主題:	Microbiome NSCLC Immunotherapy 16S rRNA Immunotherapy efficacy
在線閱讀:	https://doi.org/10.1038/s41598-025-89406-1

相似書籍

Gut resistome of NSCLC patients treated with immunotherapy
由: Ewelina Iwan, et al.
出版: (2024-08-01)

Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer
由: Anna Grenda, et al.
出版: (2022-07-01)

MicroRNA-126 selected with broad-spectrum analysis of microRNAs – a new predictive factor for the effectiveness of immunotherapy or chemoimmunotherapy in advanced NSCLC patients?
由: Anna Grenda, et al.
出版: (2024-02-01)

The influence of nutritional status, lipid profile, leptin concentration and polymorphism of genes encoding leptin and neuropeptide Y on the effectiveness of immunotherapy in advanced NSCLC patients
由: Małgorzata Frąk, et al.
出版: (2024-08-01)

Tissue MicroRNA Expression as a Predictor of Response to Immunotherapy in NSCLC Patients
由: Anna Grenda, et al.
出版: (2021-02-01)

A Phase 1/1B Trial of Pembrolizumab and Trametinib in Advanced NSCLC Enriched for KRAS Mutations
由: Jonathan W. Riess, MD, MS, et al.
出版: (2025-06-01)

Radiotherapy Improves Survival in NSCLC After Oligoprogression on Immunotherapy: A Cohort Study
由: Lauren Julia Brown, M.B.B.S., MClinTRes, FRACP, et al.
出版: (2024-10-01)

Brief Report: Not Created Equal: Survival Differences by KRAS Mutation Subtype in NSCLC Treated With Immunotherapy
由: Lova Sun, MD, MSCE, et al.
出版: (2025-01-01)

Serum and Glucocorticoid-Inducible Kinase 1 (SGK1) in NSCLC Therapy
由: Ilaria Guerriero, et al.
出版: (2020-11-01)

The role of chemoradiotherapy and immunotherapy in stage III NSCLC
由: Zsuzsanna Orosz, et al.
出版: (2024-04-01)

Dysregulation of SWI/SNF Chromatin Remodelers in NSCLC: Its Influence on Cancer Therapies including Immunotherapy
由: Yijiang Shi, et al.
出版: (2023-06-01)

Dual-target immunotherapies in NSCLC: a systematic review and meta-analysis of randomized clinical trials
由: Yike Zhang, et al.
出版: (2025-09-01)

Erratum: The landscape of immunotherapy resistance in NSCLC
由: Frontiers Production Office
出版: (2023-04-01)

Beyond clinical trials: real-world impact of immunotherapy on NSCLC in Jordan
由: Taher Abu Hejleh, et al.
出版: (2024-04-01)

PD-1/PD-L1 blockade therapy with atezolizumab: a new paradigm in the treatment of non-small cell lung cancer (NSCLC)
由: Samaneh Moradi, et al.
出版: (2025-03-01)

A Phase I Trial of Atezolizumab and Varlilumab in Combination With Radiation in Patients With Metastatic NSCLC
由: Jyoti Malhotra, MD, MPH, et al.
出版: (2024-08-01)

Novel hypoxia-related gene signature for predicting prognoses that correlate with the tumor immune microenvironment in NSCLC
由: Zhaojin Li, et al.
出版: (2023-04-01)

An Episode of Pseudothrombocytopenia during Pembrolizumab Therapy in NSCLC Patient
由: Kinga Krukowska, et al.
出版: (2020-01-01)

The Role of Eosinophils, Eosinophil-Related Cytokines and AI in Predicting Immunotherapy Efficacy in NSCLC
由: Fausto Omero, et al.
出版: (2025-03-01)

Clinical Management in NSCLC Patients With EGFR Mutation After Osimertinib Progression With Unknown Resistance Mechanisms
由: Xin Liao, et al.
出版: (2024-10-01)

Polymorphism of Baculoviral Inhibitor of Apoptosis Repeat-Containing 5 (BIRC5) Can Be Associated with Clinical Outcome of Non-Small Cell Lung Cancer
由: Michał Szczyrek, et al.
出版: (2022-03-01)

Antibiotic Use and Survival in Patients With Late-Stage NSCLC Treated With Chemoimmunotherapy
由: Emanuela Taioli, MD, PhD, et al.
出版: (2024-12-01)

Towards a survival risk prediction model for metastatic NSCLC patients on durvalumab using whole-lung CT radiomics
由: Kedar A. Patwardhan, et al.
出版: (2024-06-01)

Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
由: Johan F. Vansteenkiste, MD, PhD, et al.
出版: (2024-03-01)

The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy
由: Francis Proulx-Rocray, et al.
出版: (2023-01-01)

Update on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease
由: Arani Sathiyapalan, et al.
出版: (2023-10-01)

Case Report: Pathologic complete response in a patient with simultaneous diagnoses of resectable NSCLC and myeloid neoplasm with PDGFRA rearrangement treated with concurrent neoadjuvant chemoimmunotherapy and imatinib: translating clinical trial data to real-world practice
由: Chad B. Sussman, et al.
出版: (2025-07-01)

HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC
由: Jie Mei, et al.
出版: (2022-07-01)

Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
由: Lixiu Peng, et al.
出版: (2023-01-01)

Evaluation and modifcation of lung immune prognostic index in patients with metastatic NSCLC treated by immunotherapy
由: D. I. Yudin, et al.
出版: (2023-05-01)

Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC
由: Chengli Du, et al.
出版: (2023-12-01)

Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy Patients
由: Luigi Della Gravara, et al.
出版: (2021-06-01)

Long-term complete remission with immunotherapy in advanced RET fusion-positive NSCLC with brain metastases: a case report and literature review
由: Shuheng Shang, et al.
出版: (2025-09-01)

Feasibility and Safety of Anlotinib Plus Docetaxel versus Docetaxel Monotherapy in Patients with Previously Immunotherapy-Treated NSCLC: A Retrospective Exploratory Study
由: Li DW, et al.
出版: (2025-04-01)

Radiomics combined with transcriptomics to predict response to immunotherapy from patients treated with PD-1/PD-L1 inhibitors for advanced NSCLC
由: Amine Bouhamama, et al.
出版: (2023-05-01)

A Phase I Dose-Escalation Clinical Trial of Bronchoscopic Cryoimmunotherapy in Advanced-Stage NSCLC
由: Jun-Chieh J. Tsay, MD, MS, et al.
出版: (2025-08-01)

Expression patterns of estrogen and androgen receptors in NSCLC patients according to the PD-L1 profile
由: Vianey Rodriguez-Lara, et al.
出版: (2025-06-01)

Concurrent versus sequential immunotherapy with chemoradiotherapy for unresectable stage III non-small-cell lung cancer: a retrospective study
由: Zhou Meng-Xi, et al.
出版: (2025-01-01)

The Impact of Immunotherapy Use in Stage IIIA (T1-2N2) NSCLC: A Nationwide Analysis
由: Lye-Yeng Wong, MD, et al.
出版: (2024-03-01)

Comparative Survival Analysis of Anti‐Angiogenic Agent Plus Immunochemotherapy in NSCLC Patients After Frontline EGFR‐TKI Treatment: A Retrospective Cohort Study
由: Yi‐Tse Su, et al.
出版: (2025-07-01)